BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.09%. A quarter ago, it was expected that this drugmaker would post a loss of $0.24 per share when it actually produced a loss of $0.28, delivering a surprise of -16.67%.Over the last four quarters, the company ...

EXHIBIT 99.1 BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update —Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million— —Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) — —Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials— RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) ...

Company Overview - BioCryst Pharmaceuticals (BCRX) is expected to report a quarterly loss of $0.23 per share, reflecting a year-over-year change of +17.9% [2] - Revenues are anticipated to be $85.6 million, which is a 24.5% increase from the same quarter last year [2] - The Most Accurate Estimate for BioCryst is higher than the Zacks Consensus Estimate, indicating a bullish sentiment among analysts [5] Earnings Expectations - The upcoming earnings report is scheduled for May 6, and the stock price may react positively if actual results exceed expectations [1] - The consensus EPS estimate has been revised 2.86% lower over the last 30 days, suggesting a reassessment of earnings expectations by analysts [2] - BioCryst has an Earnings ESP of +11.11%, which suggests a likelihood of beating the consensus EPS estimate [5][6] Historical Performance - In the last reported quarter, BioCryst was expected to post a loss of $0.24 per share but actually reported a loss of $0.28, resulting in a surprise of -16.67% [7] - Over the past four quarters, BioCryst has beaten consensus EPS estimates three times [7] Industry Context - In the Zacks Medical - Drugs industry, Zoetis (ZTS) is expected to post earnings of $1.35 per share for the same quarter, indicating a year-over-year change of +3.1% [9] - Zoetis's revenue is projected to be $2.14 billion, up 7% from the previous year [9] - The consensus EPS estimate for Zoetis has been revised 0.1% lower, and it has an Earnings ESP of 0.23% combined with a Zacks Rank of 4 (Sell), making predictions about beating the consensus EPS estimate challenging [9]

RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and ...

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. "We are excited to announce that ORLADEYO is now approved in the region's largest market, following the positive regulatory decisions we received i ...

 Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more. That is precisely the potential that the stocks below offer to investors.The firms discussed below are also relatively unknown and are generally not household names. They can therefore be characterized as hidden gems given their strong potential upside. As always, invest in penny stocks what you are willing to lose. Whil ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Conference Call February 26, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - Chief Executive Officer Ryan Arnold - Chief Medical Officer Charlie Gayer - Chief Commercial Officer Anthony Doyle - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Jessica Fye - JP Morgan Liisa Bayko - Evercore ISI Stacy Ku - TD Cowen Serge Belanger - ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value BCRX Nasdaq Global Select Market Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

Company Performance - BioCryst Pharmaceuticals reported a quarterly loss of $0.28 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.24, but an improvement from a loss of $0.38 per share a year ago [1] - The company achieved revenues of $93.4 million for the quarter ended December 2023, exceeding the Zacks Consensus Estimate by 4.72% and up from $79.55 million year-over-year [1] - Over the last four quarters, BioCryst has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [1] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $85.97 million, and for the current fiscal year, it is -$0.67 on revenues of $406.94 million [4] - The estimate revisions trend for BioCryst is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [4] Industry Context - The Medical - Drugs industry, to which BioCryst belongs, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [5] - Rigel Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.04 per share, reflecting a significant year-over-year decline of 500%, with revenues projected at $33.5 million, down 34.7% from the previous year [5]

—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between $380-$400 million— —Company expects operating profit in 2024, approaching positive EPS and positive cash flow in 2H 2025— RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. ...